SRRK

$53.06-$0.76 (-1.41%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$6.6B

122M shares

52-week range

$27.07 – $58.49

83% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change+$14.17

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$7M	+4129.1%	$-3.18	$-3.59–$-2.31	—	11
2027	$149M	+2196.9%	$-2.55	$-3.13–$-2.19	—	13
2028	$361M	+141.5%	$-1.34	$-2.00–$-0.67	—	12
2029	$566M	+56.9%	$-0.28	$-0.42–$-0.10	—	9

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.84	$-0.84	+0.1%
2026-05-07	$-0.82	$-0.83	-1.2%
2026-03-03	$-0.88	$-0.88	+0.3%
2025-11-14	$-0.84	$-0.90	-7.8%
2025-08-06	$-0.66	$-0.98	-48.5%
2025-05-14	$-0.63	$-0.67	-6.3%
2025-02-27	$-0.60	$-0.60	+0.0%
2024-11-12	$-0.58

DCF fair valuemodel estimate

Intrinsic value

$1.79

Price

$53.06

Implied downside

-97%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
SRRKScholar Rock Holding Corporation	$53.49	-0.61%	$6.4B	—
ADPTAdaptive Biotechnologies Corporation	$24.68	-2.28%	$3.9B	—
BEAMBeam Therapeutics Inc.	$26.50	-0.79%	$2.7B	—
CDTXCidara Therapeutics, Inc.	$221.38	+0.00%	$5.6B	—
IDYAIDEAYA Biosciences, Inc.	$36.79

Scholar Rock Holding Corporation Common Stock

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

www.scholarrock.com

Employees: 289
IPO / List date: May 24, 2018
HQ: CAMBRIDGE, MA

Held by traders on TradeandTell

No one on the platform currently holds SRRK.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-06-30	291,200	$10.3M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded SRRK yet.

$SRRK chatter on StockTwits

R.W.@Whiskeyunderthebed3d
$SRRK can you say ready….set…GO!
View on StockTwits ↗
PRISM MarketView@prismmarketview3d
$SRRK Scholar Rock’s apitegromab BLA review is advancing through a second fill-finish facility, with the FDA data package submitted ahead of schedule. Scholar Rock says it has commercial supply ready and continues to target a potential approval decision by September 30. https://prismmarketview.com/scholar-rock-advances-apitegromab-fda-review-for-spinal-muscular-atrophy/
View on StockTwits ↗
TwongStocks@TwongStocks6d
$SRRK Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.businesswire.com/news/home/20260807011647/en/Scholar-Rock-Announces-FDA-Review-of-Apitegromab-Biologics-License-Application-BLA-for-Spinal-Muscular-Atrophy-SMA-to-Progress-with-Second-Fill-Finish-Facility-Approval-Decision-Anticipated-by-September-30-2026-Action-Date • The FDA has classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). • Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA. • FDA review of the apitegromab BLA will progress solely with the second fill-finish facility.
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Aug 6
$SRRK Was hoping the ATM offering would cause selloff to add more. GLTA
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderAug 6
https://www.marketbeat.com/earnings/reports/2026-8-6-scholar-rock-holding-co-stock/ $SRRK Scholar Rock Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 6
$SRRK Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.84 up 14.29% YoY
View on StockTwits ↗
R.W.@WhiskeyunderthebedAug 6
$SRRK
View on StockTwits ↗
R.W.@WhiskeyunderthebedAug 6
$SRRK
View on StockTwits ↗
R.W.@WhiskeyunderthebedAug 6
$SRRK
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Aug 5
$SRRK Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference Business Wire CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (SRRK.NaE) , a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET.
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Jul 23
$SRRK High on the M&A list, the weight loss product line which retains much higher % of lean mass would be gravy
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Jul 22
$SRRK Silly selloff IMO, but I'll use it as an entry point. GLTA
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Jul 22
$SRRK * The FDA is reviewing apitegromab and is expected to decide on Scholar Rock's (SRRK.NaE) application by September 30, 2026. * UBS analyst Michael Yee said the delay was expected because the European filing included only the Indiana facility, but added this was not a risk to the program, citing trial data showing improved motor function in patients treated with the drug.
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Jul 22
$SRRK The European Medicines Agency (EMA) is awaiting the U.S. Food and Drug Administration's classification of a Bloomington, Indiana situated fill-finish facility following an April inspection, Scholar Rock (SRRK.NaE) said. * A favorable FDA reclassification of the facility could clear the way for the EMA's Committee for Medicinal Products for Human Use to issue an opinion on the drug - apitegromab - later this year, said Scholar Rock (SRRK.NaE). * If the facility is not cleared, the company plans to work with European regulators to advance the application using a second fill-finish facility already included in its U.S. regulatory filing. * Scholar Rock (SRRK.NaE) said the second site makes commercial products and is in good standing with U.S. and European regulators. * CEO David Hallal said Scholar Rock (SRRK.NaE) remains confident it can complete the European review process using either manufacturing site.
View on StockTwits ↗
Tom Dorsey@Tdorsey1776Jul 22
$SRRK $LLY Love this combo, too much lean mass is lost on GLP-1s..... SCHOLAR ROCK (SRRK) Last year, the company said its experimental drug, apitegromab, combined with Lilly's Zepbound, helped patients preserve significantly more lean mass in a mid-stage trial. In Scholar Rock's (SRRK) study, patients who received a combination of tirzepatide - the active ingredient in Zepbound - and Scholar's apitegromab lost 3.4 pounds of lean mass after 24 weeks, compared with those on tirzepatide alone, who lost 7.6 pounds of lean mass.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.